A034940 logo

ChoA Pharmaceutical Co., LTD. Stock Price

KOSDAQ:A034940 Community·₩27.0b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A034940 Share Price Performance

₩0
-1094.00 (-100.00%)
₩0
-1094.00 (-100.00%)
Price ₩0

A034940 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Low risk and slightly overvalued.

3 Risks
0 Rewards

ChoA Pharmaceutical Co., LTD. Key Details

₩59.3b

Revenue

₩37.4b

Cost of Revenue

₩21.9b

Gross Profit

₩28.7b

Other Expenses

-₩6.8b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-219.68
36.88%
-11.47%
114.8%
View Full Analysis

About A034940

Founded
1964
Employees
n/a
CEO
Sung-Hwan Cho
WebsiteView website
www.choa.co.kr

ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral nervous system; gynecologic diseases; antibiotics, antigens, and anthelmintic; and antitumor, as well as other metabolite medicines. The company offers its products in the form of tablets, capsules, granules, syrups, solutions, drinkable ampoules, and sachets. It also provides medicine supply and pharmacy management services. The company exports its products to approximately 20 countries worldwide. The company was founded in 1964 and is headquartered in Seoul, South Korea.

Recent A034940 News & Updates

Unpleasant Surprises Could Be In Store For ChoA Pharmaceutical Co., LTD.'s (KOSDAQ:034940) Shares

Feb 06
Unpleasant Surprises Could Be In Store For ChoA Pharmaceutical Co., LTD.'s (KOSDAQ:034940) Shares

Recent updates

No updates